公司概述
FibroBiologics, Inc. operates as a clinical-stage biotechnology company dedicated to the development and commercialization of fibroblast-based therapies designed for patients suffering from chronic diseases, with a specific focus on wound treatment through its product pipeline. The company functions within the broader healthcare sector and specifically the biotechnology industry, positioning itself as a specialized entity focused on translating advanced biological research into therapeutic interventions for unmet medical needs. Currently, the enterprise maintains a market capitalization of $6.27 million and employs a workforce of 15 individuals, reflecting a lean organizational structure typical of early-stage biotech firms. The combination of a sub-$10 million market cap and negligible annual revenue indicates that the company remains in an embryonic stage of commercialization, where capital allocation is primarily directed toward research and development rather than market penetration or profitability generation.
财务健康
The company reports no reported revenue or price-to-sales figures, while its trailing twelve-month net income stands at a significant loss of $-18,646,000 and its EBITDA is recorded at $-16,405,000, suggesting that the gap between revenue and net income is not applicable in the traditional sense due to the absence of commercial sales, yet the substantial negative earnings highlight the heavy cost structure associated with clinical-stage drug development activities. Free cash flow for the trailing twelve months is $-9,968,125, which indicates that the company is currently burning through cash reserves to fund its operations and pipeline progression rather than generating positive cash flow from business activities. All three margin metrics—gross margin, operating margin, and profit margin—are reported at 0.0%, a figure that technically reflects the lack of revenue generation in the current fiscal period rather than a failure to control costs, as these percentages are mathematically undefined when the denominator is zero or negligible. On the balance sheet, the company holds $4.89 million in cash against $2.41 million in debt, resulting in a debt-to-equity ratio of 39.15, which suggests a leveraged capital structure where equity is relatively low compared to the debt obligation, a common characteristic for capital-intensive biotech ventures seeking funding to reach clinical milestones. The current ratio stands at 3.61, indicating that the company possesses ample short-term liquid assets relative to its current liabilities, providing a buffer to meet near-term financial obligations despite the ongoing cash burn. Return on Equity is reported at -419.4% and Return on Assets at -79.8%, revealing that management is currently unable to generate positive returns on the capital invested by shareholders or held on the asset sheet, a metric expected in pre-revenue biotechnology companies but indicative of significant financial pressure.
估值评估
The trailing P/E ratio is listed as N/A due to negative earnings, while the forward P/E is calculated at -0.26, a negative valuation metric that implies the market is pricing in future earnings growth that is currently absent or that the company is expected to remain unprofitable for the foreseeable future. The price-to-book ratio is 0.75, indicating that the market values the company at approximately 25% less than the book value of its assets, which may reflect the high risk profile associated with the clinical-stage nature of its business and the potential dilution of assets if clinical trials fail. The price-to-sales ratio and EV/EBITDA are both listed as N/A or negative (-0.13 for EV/EBITDA), suggesting that traditional revenue-based or cash-flow-based valuation models are not applicable, as the company lacks sufficient positive earnings or sales to establish a meaningful multiple. The 52-week high is $30.60 and the 52-week low is $1.03, meaning the current trading price sits within a highly volatile range that has seen an expansion of nearly 30 times from its recent trough to its peak. The beta value is 1.10, which signifies that the stock's price volatility is 10% higher than the broader market, reflecting the elevated risk premium demanded by investors for exposure to a small-cap biotechnology firm with uncertain regulatory and commercial outcomes.
Growth & Income
The company reports N/A for both revenue growth year-over-year and earnings growth year-over-year, as these metrics are not calculable when there is no baseline revenue or when earnings are consistently negative, implying that growth rates are currently driven by pipeline milestones rather than commercial expansion. Since FibroBiologics, Inc. does not pay a dividend, the dividend yield is N/A and the payout ratio is 0.0%, indicating that the company does not distribute any portion of its earnings to shareholders and instead retains all available capital to fund its research and development efforts. Consequently, the company reinvests its limited cash reserves and any potential future proceeds directly into advancing its fibroblast-based therapies through clinical trials rather than providing income distributions to investors. The overall growth and income profile is characterized by a complete absence of current financial returns, with the sole value proposition derived from the potential success of the CYWC628 product candidate in treating chronic diseases and wounds.